Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12029-013-9536-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive Value of Magnetic Resonance Complete Response After Neoadjuvant Therapy for Rectal Cancer.
J Surg Res
January 2025
Department of Surgery, Stanford University School of Medicine, Stanford, California; S-SPIRE Center, Department of Surgery, Stanford University School of Medicine, Stanford, California.
Introduction: Previous research has demonstrated that after neoadjuvant therapy for rectal cancer, the sensitivity of magnetic resonance complete response (mrCR) for detecting pathologic complete response (pCR) in the surgical specimen ranges from 74 to 94%. Patient and provider interest in nonoperative management of rectal cancer that responds favorably to neoadjuvant therapy has grown, necessitating stronger evidence for how well radiographic complete response truly predicts pCR. We sought to determine the current association between mrCR and pCR in locally advanced rectal cancer.
View Article and Find Full Text PDFOrgan preservation, for rectal cancer: general overview of the latest data from phase III randomized trials.
Acta Oncol
January 2025
Department of Radiotherapy, Antoine Lacassagne Center, Nice, France.
Introduction: Organ preservation (OP) strategies are gaining interest in improving the quality of life in the management of rectal cancer, particularly for tumors located in the distal or middle rectum. The optimal OP protocol is still not standardized and relies on randomized trials. This review summarizes past and ongoing studies on OP protocols for adenocarcinoma of the distal and middle rectum.
View Article and Find Full Text PDFThree effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report.
J Med Case Rep
January 2025
Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, 1-5-7, Asahimachi, Abeno-Ku, Osaka, 545-8585, Japan.
Background: The Barcelona Clinic Liver Cancer staging system classifies hepatocellular carcinoma on the basis of tumor characteristics, liver function, and Eastern Cooperative Oncology Group performance status. Hepatocellular carcinoma is divided into five stages, and the treatment options for intermediate-stage hepatocellular carcinoma have evolved in recent years. Transcatheter arterial chemoembolization remains the standard treatment for intermediate-stage (stage B) hepatocellular carcinoma.
View Article and Find Full Text PDFPatterns, timing and predictors of recurrence following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: an international multicentre retrospective cohort study.
HPB (Oxford)
December 2024
University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom. Electronic address:
Background: Most patients undergoing pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) develop recurrence. No previous studies have investigated predictors of local-only recurrence following PD for PDAC. Our study aimed to determine timing, pattern and predictors of any-site and local-only recurrence following PD for PDAC.
View Article and Find Full Text PDFPrimary squamous cell carcinoma of the pancreas: A case report.
Int J Surg Case Rep
January 2025
Department of Hepatopancreatobiliary Surgery, First People's Hospital of Jiashan County, Jiaxing, Zhejiang Province, China.
Introduction: Primary squamous cell carcinoma (SCC) is a rare type of pancreatic cancer with an extremely low incidence rate and a prognosis that is poorer than that of pancreatic ductal adenocarcinoma.
Presentation Of Case: We report a case of pure pancreatic SCC in an 80-year-old man. Based on the examination before surgical resection, we did not detect any SCC lesions that might have metastasized to the pancreas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!